Before your video consultation, a transplant specialist should already have reviewed more than your HIV diagnosis. Your records should show why a stem cell transplant is being considered, what treatment you have received, how well HIV is controlled, and whether a serious blood or bone marrow disorder independently warrants transplantation.

That distinction shapes the entire call. Stem cell transplantation is not a routine or approved cure for HIV/AIDS. The rare reports of long-term HIV remission followed high-risk transplants performed primarily for life-threatening blood cancers. A careful overseas consultation tests whether a proposed treatment is appropriate for your underlying illness, rather than treating remission headlines as a promise.

First, the specialist checks what your HIV and blood-disorder records actually show

The consultation should begin with your HIV history: your viral load (the amount of HIV measured in blood), CD4 count (a measure of immune-system cells), antiretroviral therapy or ART, resistance test results, and any AIDS-defining illness. An AIDS diagnosis signals advanced immune damage or particular serious infections. It does not, by itself, create an indication for transplantation.

If you also have cancer, the specialist should explain its type, extent, previous response to treatment, and why transplantation is being discussed. This may involve acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), high-risk myelodysplastic syndrome (MDS), or selected relapsed or treatment-resistant Hodgkin or non-Hodgkin lymphoma. Multiple myeloma and other serious blood disorders may also justify transplantation in some patients. The transplant decision depends on the blood disease, not simply on the presence of HIV.

Reports may describe remission, meaning the cancer is not detectable by standard tests, or relapse, meaning it has returned. For leukemia and MDS, bone marrow findings, genetic markers, and the proportion of abnormal cells help define risk. For lymphoma or myeloma, scans, pathology, marrow testing, and treatment response help establish the disease stage and next treatment choice. Ask the consultant to explain which findings matter most in your case.

Ask back: “What diagnosis and disease-risk category are you using, and which report establishes them?” A clear answer names the relevant pathology, marrow, imaging, or laboratory result, acknowledges any missing information, and explains why that finding changes the treatment plan.

Next, the specialist tests whether transplantation is safe enough to consider

A preliminary decision can be made from records sent from home, but it is not final clearance. The overseas team should assess your heart, lungs, kidneys, and liver, review past infections and other conditions, and determine whether your blood disease is at a point where transplantation could help. An HIV specialist should be involved in planning ART and infection prevention alongside the transplant team.

Age alone does not decide eligibility. Frailty, diabetes control, smoking, high body mass index, organ damage, previous chemotherapy, and the ability to manage intensive follow-up may matter more. Active serious infection or poorly controlled HIV can increase risk or require treatment before a transplant decision. The specialist should explain which factors can be improved and which could rule out the proposed approach.

For a donor transplant, the team also needs a feasible donor search. HLA matching compares immune-system markers to help select a donor. Finding a donor with both an acceptable match and two copies of the CCR5-Δ32 mutation is particularly difficult. This inherited change removes a cell entry point used by many, but not all, strains of HIV. It is not a substitute for choosing a donor who is medically suitable for treating your blood disorder.

Ask back: “Am I being assessed for a transplant because of my blood disorder, and what could change your decision after I arrive?” A clear answer separates preliminary remote eligibility from the in-person examination, repeat testing, and final approval.

Then, the consultant explains what could help without an overseas transplant

If you have HIV without a transplant-eligible blood disorder, ongoing ART remains the proven foundation of care. Clinical research into HIV remission or cure is different from standard treatment. A legitimate study has eligibility rules, oversight, informed consent, monitoring, and a plan for what happens if the intervention fails or causes harm. Paying for unproven injections is not the same as joining a clinical trial.

If you have a blood cancer, alternatives depend on its type and response. They may include further drug treatment, targeted or immune-based treatment, supportive care, an autologous transplant using your own cells, or a donor transplant at home. Some patients may benefit from a second opinion without traveling for the procedure. Access to a particular donor strategy or research protocol may be a reason to compare overseas centers, but travel also complicates continuity and urgent care.

This comparison keeps the purpose of treatment clear:

Ask back: “What would you recommend if I stayed home, and why is your proposed option preferable for my blood disease?” A clear answer discusses realistic alternatives, access, risks, and follow-up rather than assuming treatment abroad is better.

Only after that should the specialist describe the cells and the transplant process

“Stem cell therapy” can mean very different things. A legitimate hematopoietic stem cell transplant uses blood-forming cells collected from blood, bone marrow, or donated cord blood. An autologous transplant uses your cells. An allogeneic transplant uses donor cells and can replace parts of the immune system, but it brings additional risks.

The consultant should identify the cell source, donor type, HLA-matching approach, and whether CCR5-Δ32 testing is part of the plan. They should also specify the conditioning regimen, meaning the chemotherapy or other treatment given before infusion, and the medicines planned to reduce rejection and graft-versus-host disease. These details vary among centers. If gene-edited cells, CCR5-modified cells, or immune-cell products are proposed, ask for the exact product or study protocol and its regulatory status in writing, not just a familiar-sounding technique name.

A donor transplant generally follows this sequence, although your team may adapt it to your disease:

1. Confirm the plan. The team repeats key tests, checks infections and organ function, reviews ART interactions, and confirms donor suitability.
2. Prepare the body. Conditioning treats the blood disease and makes room for donor cells. The intensity depends on your health and cancer.
3. Infuse the cells. Stem cells are given through a vein, usually through an existing central line. This infusion is not surgery on the HIV reservoir.
4. Support engraftment. The team monitors blood counts while donor cells begin producing new blood cells. Transfusions, infection treatment, and other supportive care may be needed.
5. Monitor both diseases. Follow-up tracks cancer response, immune recovery, complications, HIV viral load, and the continuing ART plan.

Ask back: “Whose cells would I receive, how are they matched and tested, and what exactly would happen before and after infusion?” A clear answer identifies the cell source and proposed regimen, explains who performs each part, and does not describe an ordinary cell injection as equivalent to a transplant.

The safety discussion must include risks that cannot be managed over video

Transplant risks include severe infection, bleeding while blood counts are low, organ toxicity, infertility, cancer relapse, and treatment-related death. Donor transplants can also cause graft-versus-host disease (GVHD), in which donor immune cells attack your tissues. GVHD can affect the skin, gut, liver, and other organs. Teams may use preventive medicines and treat complications as they appear, but prevention does not remove the risk.

Published GVHD figures across allogeneic transplant settings can span roughly 20% to 70%, depending heavily on what is counted, donor and graft type, and preventive treatment. This is not a personalized HIV-specific estimate. Infection, organ injury, and treatment-related death also vary substantially by disease, donor, conditioning, and health status. Ask the center for its complication and survival ranges for patients comparable to you, including how it defines and measures each outcome.

Distance adds another layer of risk. A fever or new symptom after you return home may require immediate examination, laboratory tests, or admission locally. The overseas team can review records and advise your doctors, but it cannot provide emergency treatment remotely. A credible plan names the hospital responsible for urgent care after your return and explains how the two teams will communicate.

Ask back: “Which complications are most likely for me, how often do they occur in comparable patients, and who treats them after I return?” A clear answer gives relevant ranges where available, admits uncertainty, and identifies both an on-site response and a local emergency pathway.

A realistic results discussion separates cancer control from HIV remission

A transplant’s primary success measure is whether it treats the blood disorder with an acceptable burden of harm. That outcome varies by diagnosis, disease status, donor, and your general health. The consultant should provide a prognosis based on patients like you, including the chance of relapse and the possibility that the transplant itself causes serious harm.

Long-term HIV remission after donor transplantation has been documented in a very small number of highly selected people. There is no reliable success percentage that can be applied to a patient booking treatment abroad. Even a CCR5-Δ32 donor does not guarantee remission, because HIV biology and the persistence of infected cells are complex. Autologous transplantation for a condition such as multiple myeloma is not expected to clear HIV.

You should expect to continue ART unless your HIV specialists direct otherwise under an appropriate, closely monitored research protocol. An undetectable blood viral load while taking ART is a treatment success, but it does not show that HIV is gone.

Ask back: “What result are you trying to achieve for my blood disease, and what, if anything, can you reasonably predict for HIV?” A clear answer gives separate goals and explains how and for how long each will be monitored, without guaranteeing HIV remission.

Before travel, the call should become a shared medical and practical plan

Most preparation starts at home. Your HIV and hematology teams may need to update tests, address infections, review vaccination history, assess fertility-preservation options, and check interactions between ART and transplant medicines. Do not change or stop medications on your own. Ask who will make each decision and whether records from different specialists have been reconciled.

You should also compare the actual treating programs, not only their proposals. Ask whether the facility is licensed for the proposed cell collection and transplantation, whether its transplant program has relevant accreditation, and how donor testing, cell processing, infection control, intensive care, and HIV specialist support are arranged. If a research intervention is offered, request its registration, oversight details, eligibility criteria, and consent documents. Specialist expertise should cover both the blood disease and HIV care.

A written quote should distinguish the transplant itself from the total cost of traveling for treatment. Confirm whether consultations, repeat tests, donor search and collection, cell processing, conditioning, medicines, hospital care, management of complications, accommodation, transfers, and follow-up are included or excluded. Donor availability, disease complexity, hospital needs, and unexpected complications can change the final amount. Obtain inclusions, exclusions, and payment conditions in writing. The cheapest plan is not automatically the safest clinical fit.

When comparing destinations, focus on transplant capability, donor access, HIV-transplant coordination, regulatory oversight, and whether your local doctors can continue the care plan. Arrival, time near the treating team, and readiness to fly depend on final testing, engraftment, complications, and your ability to attend close follow-up. A companion may be useful during intensive treatment and early recovery. A PlacidWay patient coordinator can help with destination options, prices, and travel arrangements.

Ask back: “What must be completed at home, what might change after an in-person assessment, and what is excluded from this quote?” A clear answer provides a named clinical contact, a conditional treatment plan, and written cost and follow-up details before you commit.

Finally, the consultant should map recovery from the treating center to home

Recovery is not over when the cell infusion ends. Your team watches for low blood counts, infection, and early organ problems while new cells take hold. After discharge, frequent appointments may still be needed for tests, medication adjustments, and signs of GVHD. Your ability to leave the destination should be based on clinical stability and a safe handover, not a fixed travel date.

Before you leave, request a discharge summary, transplant and cell-product details, donor and HLA information where applicable, conditioning and complication records, laboratory trends, prescriptions, infection-prevention instructions, and a written testing schedule. Your home doctor should receive the same plan. It should name an emergency contact at the overseas center and clarify who reviews results, prescribes ongoing medicines, and makes decisions if cancer relapses or GVHD develops.

Seek urgent local assessment for fever, breathing trouble, severe diarrhea, new rash, jaundice, bleeding, confusion, or a sudden decline in how you feel. Do not wait for a remote reply when symptoms may need emergency care. Later complications might be managed jointly through records and video review, but admission, procedures, or a further transplant decision could require local treatment or another trip. Establish responsibility for those possibilities before traveling.

Ask back: “What must be true before I can return home, and who takes responsibility if a complication appears there?” A clear answer gives medical discharge criteria, specific warning signs, a local-care handover, remote-follow-up arrangements, and a plan for complications that cannot be handled remotely.

Take the next step with a clear HIV and transplant proposal

If you are considering a transplant or a research consultation abroad, speak with a PlacidWay patient coordinator about finding a provider who can review your records and explain a treatment-specific plan.

Request information

References

• National Cancer Institute, Stem Cell Transplants in Cancer Treatment.
• HIV.gov, HIV Basics.
• National Institutes of Health, Clinical Guidelines for HIV Care.
• U.S. Food and Drug Administration, Consumer Alert on Regenerative Medicine Products, Including Stem Cells.
• ClinicalTrials.gov, Clinical Studies Registry.

This page is for general information and is not medical advice. Consult qualified HIV and transplant specialists about your own diagnosis, treatment options, and travel plans.